Lumida
/ALEC
⌘K
Alector Inc

Alector Inc

ALEC
$2.30USD-2.54%-0.06 today

MARKET CAP

256.8M

P/E (TTM)

FWD P/E

DAY RANGE

$2 – $2

52W RANGE

$1
$3

AI Summary

Stalk
TrimMedium

Despite the mid-June Bearish Exhaustion bounce, ALEC remains in a Stage 4 decline with both long- and medium-term downtrends intact. The exhaustion pattern indicates only a potential counter-trend bounce, not a sustained reversal. Short-term momentum above the 9/21 EMAs improves timing for a sell entry but price remains below key 50- and 200-day DMAs. As a result, medium-term bias stays bearish and sell-side execution should be deferred into resistance zones around the declining 50 DMA and prior support, anticipating rejection.

  • Phase 2 INVOKE readout expected Q4 2024; strong biomarkers may drive FDA approval.
  • Cash balance of $172.8 M funds operations through 2027, avoiding near-term dilution.
  • Collaboration revenue fell from $79.9 M to $56.2 M, underscoring volatility.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$207.1M$133.6M$97.1M$100.6M$21.0M
YoY %+881.5%-35.5%-27.4%+3.6%-79.1%
P / Sales8.0x5.6x6.9x1.8x7.6x
EV / Sales8.9x8.8x11.1x4.9x17.0x
Gross Profit, Adj.$207.1M$133.6M$97.1M$100.6M$21.0M
YoY %+881.5%-35.5%-27.4%+3.6%-79.1%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit8.9x8.8x11.1x4.9x17.0x
EBITDA, Adj.$-31.0M$-132.1M$-146.0M$-139.6M$-150.3M
YoY %+83.6%-325.8%-10.5%+4.4%-7.7%
Margin %-15.0%-98.9%-150.4%-138.8%-714.1%
EV / EBITDA-59.5x-8.9x-7.4x-3.5x-2.4x
EBIT$-37.4M$-137.8M$-151.7M$-145.0M$-156.0M
YoY %+80.9%-268.9%-10.1%+4.4%-7.6%
Margin %-18.0%-103.2%-156.3%-144.2%-741.3%
EV / EBIT-49.4x-8.5x-7.1x-3.4x-2.3x
Net Income$-36.3M$-133.3M$-130.4M$-119.0M$-142.9M
YoY %+80.9%-267.0%+2.2%+8.7%-20.1%
Net Margin-17.5%-99.8%-134.3%-118.4%-679.2%
EPS (GAAP)-$0.45-$1.62-$1.56-$1.23-$1.39
YoY %+81.6%-260.0%+3.7%+21.2%-13.0%